Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-Related Macular Degeneration (AMD) at Association for Research in Vision & Ophthalmology 2013 Annual Meeting
5/9/2013 7:34:59 AM
More...
|
FDA Accepts Otsuka Pharmaceutical Co., Ltd. Tolvaptan NDA for Priority Review
4/15/2013 8:49:26 AM
More...
|
Otsuka Pharmaceutical Co., Ltd.'s New Drug Application for Tolvaptan, the Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Accepted for Review by the FDA
4/12/2013 9:47:08 AM
More...
|
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO) Enter $825 Million Deal for Alzheimer's Drug
3/26/2013 7:03:04 AM
More...
|
Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S (LUN.CO) Wins Approval for Monthly Abilify Shot
3/1/2013 7:26:41 AM
More...
|
Otsuka Pharmaceutical Co., Ltd. and Lundbeck Inc. (LUN.CO) Initiate the Regulatory Process for Aripiprazole (Once-Monthly) Depot Formulation in Europe
12/27/2012 9:40:22 AM
More...
|
Living Cell Technologies Ltd. and Otsuka Pharmaceutical Co., Ltd. to Co-Develop NTCELL® for Parkinson's Disease
12/17/2012 3:32:35 PM
More...
|
Catalent Pharma Solutions Announces Commencement of Supply of Abilify® Orally Disintegrating Tablets to Otsuka Pharmaceutical Co., Ltd. and Extensive Investments to Its Zydis® Technology Capabilities in Swindon, UK
7/24/2012 9:55:06 AM
More...
|
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients With Dry Eye Syndrome
7/19/2012 10:02:54 AM
More...
|
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
7/6/2012 9:51:17 AM
More...
|
|